BioSpace News Archive

Nurix Therapeutics, Inc., a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, announced that Hans van Houte, Nurix’s chief financial officer, and Jason Kantor, Ph.D., Nurix’s chief business officer will participate in the following conferences in March.

Cardiff Oncology, Inc. (Nasdaq: CRDF) today announced publications of five abstracts that will be presented in a poster session at the American Association for Cancer Research (AACR) Annual Meeting, taking place from April 5-10, 2024, in San Diego, California.

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) today announced that the Company’s senior management team will participate in the Leerink Partners Global Biopharma Conference on Tuesday, March 12, 2024 and present at the Barclays 26th Annual Global Healthcare Conference in a fireside chat on Wednesday, March 13, 2024 at 9:00 a.m. ET in Miami Beach, FL.

The U.S. Food and Drug Administration is taking several additional steps to address concerns about elevated lead levels in cinnamon following the recent incident associated with certain cinnamon apple sauce pouches that resulted in lead poisoning in young children.

ORIC Pharmaceuticals, Inc., a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, announced that management will present a company overview at the Leerink Partners Global Biopharma Conference on Wednesday, March 13, 2024, at 8:00 a.m. ET.

Avid Bioservices, Inc. announced that it intends to offer, subject to market conditions and other factors, $160 million aggregate principal amount of Convertible Senior Notes due 2029 in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Section 4 of the Securities Act of 1933, as amended.

Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the fourth quarter and full-year ended December 31, 2023.

INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced its financial results and operational highlights for the fourth quarter and full year ended December 31, 2023.

ChromaDex Corp. announced fourth quarter and fiscal year 2023 financial results. Fourth Quarter 2023 and Recent Highlights Total net sales of $21.2 million, with $17.6 million from Tru Niagen®, up 1% and 9%, respectively, from the prior year quarter.

Talphera, Inc. (Nasdaq: TLPH), (“Talphera”), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced fourth quarter 2023 financial results and provided a corporate update.